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 Introduction.	  The	  individual	  response	  to	  vitamin	  K	  antagonists	  (VKA)	  is	  highly	  variable,	  being	  influenced	  by	  clinical	  factors	  and	  genetic	  variants	  of	  enzymes	  that	  are	  involved	  in	  the	  metabolism	  of	  VKA	  (CYP2C))	  	  and	  vitamin	  K	  (VKORC1).	  Currently,	  the	  dose	  of	  VKA	  is	  adjusted	  based	  on	  measurements	  of	  the	  prothrombin	  time.	  In	  the	  last	  years,	  mathematical	  algorithms	  were	  developed	  for	  estimating	  the	  appropriate	  VKA	  dose,	  based	  on	  different	  mathematical	  approaches	  working	  on	  clinical	  and	  genetic	  data.	  Artificial	  Neural	  Networks	  (ANN)	  are	  computerized	  algorithms	  resembling	  interactive	  processes	  of	  the	  human	  brain,	  which	  allow	  to	  study	  very	  complex	  non-­‐linear	  phenomena	  like	  biological	  systems.	  Aim.	  To	  evaluate	  the	  performance	  of	  new	  generation	  ANN	  on	  a	  large	  data	  base	  of	  patients	  on	  chronic	  VKA	  treatment.	  Methods.	  Clinical	  and	  genetic	  data	  from	  377	  patients	  (186	  m;	  191	  f)	  treated	  with	  a	  VKA	  (warfarin)	  average	  weekly	  maintenance	  dose	  (WMD)	  of	  23.7	  mg	  (11.5	  SD)	  were	  used	  to	  create	  a	  dose	  algorithm.	  Forty-­‐eight	  variables,	  including	  demographic,	  clinical	  and	  genetic	  data	  (5	  CYP2C9	  and	  3	  VKORC1	  genetic	  variants)	  were	  entered	  into	  Twist®	  system,	  which	  can	  select	  fundamental	  variables	  during	  their	  evolution	  in	  search	  for	  the	  best	  predictive	  model.	  The	  final	  model,	  based	  on	  23	  variables	  expressed	  a	  functional	  approximation	  of	  the	  actual	  dose	  within	  a	  validation	  protocol	  based	  on	  a	  tripartite	  division	  of	  the	  data	  set	  (training,	  testing,	  validation).	  Results.	  In	  the	  validation	  cohort,	  the	  pharmacogenetic	  algorithm	  reached	  high	  accuracy,	  with	  an	  average	  absolute	  error	  of	  5.7	  mg	  	  WMD.	  In	  the	  subset	  of	  patients	  requiring	  ≤21	  mg	  (45	  %	  of	  the	  cohort)	  and	  21-­‐49	  mg	  (51	  %	  of	  the	  cohort)	  the	  absolute	  error	  was	  3.86	  mg	  and	  5.45	  with	  a	  high	  percentage	  of	  subjects	  being	  correctly	  identified	  (72%,	  74%	  respectively).	  Conclusion.	  	  ANN	  can	  be	  applied	  successfully	  for	  VKA	  maintenance	  dose	  prediction	  and	  represent	  a	  robust	  basis	  for	  a	  prospective	  multicentre	  clinical	  trial	  of	  the	  efficacy	  of	  genetically	  informed	  dose	  estimation	  for	  patients	  who	  require	  VKA.	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INTRODUCTION	  
	  Vitamin	  K	  antagonists	  	  (VKA)	  are	  widely	  used	  in	  primary	  and	  secondary	  prophylaxis	  of	  venous	  	  thromboembolism	  and	  cardioembolism	  (Ansell	  J,	  2008).	  	  The	  use	  of	  VKA	  in	  clinical	  practice	  is	  challenging	  because	  VKAs:	  i)	  have	  a	  narrow	  therapeutic	  window	  ii)	  have	  a	  pronounced	  inter-­‐individual	  variability	  in	  dose	  requirement	  due	  to	  demographic	  and	  clinical	  factors,	  such	  as	  age,	  weight,	  height,	  comorbid	  medical	  conditions,	  concurrent	  medications,	  diet,	  ethnicity	  (Hirsh	  J,	  2003),	  and	  genetic	  factors	  (Loebstein	  R,	  2001).	  Among	  the	  latter,	  which	  are	  responsible	  for	  approximately	  30-­‐50%	  of	  response	  variability	  (Lubitz	  SA,	  2010),	  polymorphisms	  of	  two	  enzymes	  are	  strongly	  associated	  with	  dose	  requirements	  of	  VKAs:	  isoform	  CYP2C9	  of	  cytochrome	  P450	  (CYP)	  and	  vitamin	  K	  epoxide	  reductase	  complex	  subunit	  1	  (VKORC1).	  CYP2C9	  is	  the	  major	  enzyme	  involved	  in	  the	  clearance	  of	  warfarin,	  while	  VKORC1	  is	  essential	  for	  the	  regeneration	  of	  reduced	  vitamin	  K,	  which	  catalyzes	  the	  γ-­‐carboxylation	  of	  coagulation	  factors	  II,	  VII,	  IX	  and	  X,	  and	  other	  proteins.	  For	  the	  above	  reasons,	  treatment	  with	  VKA	  is	  routinely	  monitored	  by	  the	  prothrombin	  time,	  	  expressed	  as	  International	  Normalized	  Ratio	  (INR),	  with	  the	  aim	  of	  constantly	  maintaining	  the	  degree	  of	  inhibition	  of	  coagulation	  within	  the	  therapeutic	  range.	  Due	  to	  the	  many	  variables	  that	  are	  involved,	  it	  is	  difficult	  to	  predict	  the	  daily	  maintenance	  dose	  of	  warfarin,	  which	  varies	  by	  a	  factor	  of	  10	  among	  patients	  (Takahashi	  H,	  2001).	  	  The	  consequences	  of	  incorrect	  dosing	  can	  be	  dramatic,	  contributing	  to	  the	  development	  of	  thromboembolic	  events,	  in	  case	  of	  under-­‐dosing,	  or	  bleeding	  complications,	  in	  case	  of	  over-­‐dosing	  (Wysowski	  DK,	  2007).	  It	  has	  been	  reported	  that	  warfarin	  is	  the	  most	  common	  drug	  implicated	  in	  emergency	  room	  visits	  for	  adverse	  drug	  events	  in	  older	  adults	  in	  the	  United	  States	  (U.S.	  FDA,	  2008).	  Although	  new	  oral	  anticoagulants	  (NOA)	  with	  favourable	  risk-­‐to-­‐benefit	  ratios	  and	  no	  need	  for	  laboratory	  moniroring	  (Tripodi	  A,	  2013),	  are	  being	  gradually	  	  introduced	  in	  the	  clinical	  practice,	  they	  will	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probably	  never	  completely	  replace	  VKA.	  Therefore,	  there	  still	  is	  a	  need	  to	  improve	  our	  ability	  to	  predict	  the	  effective	  dose	  of	  VKA	  in	  each	  individual	  patient.	  Among	  Caucasians,	  the	  most	  frequent	  CYP2C9	  variant	  genotypes	  are	  CYP2C9*2	  (12-­‐27%)	  and	  CYP2C9*3	  (8-­‐29%)(Margaglione	  M,	  2000;	  Scordo	  MG,	  2001;	  Sanderson	  S,	  2005;	  Spreafico	  M,	  2008;	  Sipeky	  C	  2009;	  Jorgensen	  AL,	  2012),	  which	  are	  associated	  with	  reduced	  clearance	  of	  warfarin	  	  and	  explain	  17-­‐30%	  of	  warfarin	  dose	  variability	  (McClain	  MR,	  2008;	  Wadelius	  M,	  2009,	  Jorgensen	  AL,	  2012).	  	  VKORC1	  variant	  genotypes	  are	  also	  common	  among	  Caucasians	  and	  are	  associated	  with	  increased	  sensitivity	  to	  warfarin	  (Geisen	  C,	  2005),	  accounting	  for	  approximately	  23%	  of	  warfarin	  dose	  variability	  (Geisen	  C	  2005;	  McClain	  MR,	  2012,).	  Warfarin	  dosing	  algorithms	  have	  been	  developed	  to	  improve	  our	  ability	  to	  predict	  the	  effective	  warfarin	  dose	  in	  each	  individual	  patient.	  Genotype-­‐based	  dosing	  algorithms	  predict	  37-­‐55%	  of	  the	  variation	  in	  warfarin	  dose	  requirements;	  neither	  the	  addition	  of	  race,	  number	  of	  concurrent	  medications	  nor	  the	  number	  of	  concurrent	  medications	  interacting	  with	  warfarin	  enhanced	  algorithm	  performance	  (Lubitz	  SA,	  2010).	  	  Artificial	  neural	  network	  (ANN)	  are	  computerized	  algorithms	  resembling	  interactive	  processes	  of	  human	  brain,	  which	  allow	  studying	  very	  complex	  non-­‐linear	  phenomena	  like	  biological	  systems.	  ANNs	  can	  learn	  experiential	  knowledge	  expressed	  through	  internal	  connections	  in	  a	  similar	  way	  as	  neurons	  in	  the	  brain	  and	  this	  knowledge	  can	  be	  made	  available	  for	  clinical	  decision-­‐making	  (Cross	  SS,	  1995;	  Dayhoff	  JE,	  2001).	  Given	  the	  complexity	  of	  multiple	  factors	  interplay	  behind	  optimal	  warfarin	  response	  these	  tool	  might	  offer	  a	  substantial	  advantage	  over	  other	  statistical	  approaches.	  The	  aim	  of	  this	  study	  was	  to	  evaluate	  the	  performance	  of	  new	  generation	  ANNs	  to	  predict	  the	  maintenance	  dose	  of	  warfarin,	  using	  a	  large	  database	  of	  patients	  on	  chronic	  warfarin	  treatment	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METHODS	  Patient	  characteristics	  Data	  from	  patients	  who	  were	  treated	  with	  warfarin	  between	  December	  2008	  and	  February	  2009	  were	  included	  in	  the	  analysis	  after	  having	  obtained	  written	  informed	  consent.	  The	  patients	  were	  recruited	  at	  the	  Ospedale	  San	  Paolo,	  Università	  degli	  Studi	  di	  	  Milano,	  Milan,	  Italy.	  Written	  informed	  consent	  was	  obtained	  from	  all	  patients	  and	  the	  study	  was	  approved	  by	  the	  Ethics	  Committee	  of	  Ospedale	  San	  Paolo.	  The	  study	  was	  conducted	  in	  accordance	  with	  the	  Helsenki	  Declaration.	  Patients	  were	  enrolled	  in	  the	  study	  if	  they	  were	  Caucasians,	  ≥18	  years	  of	  age,	  treated	  with	  warfarin	  for	  any	  clinical	  indication,	  	  and	  if	  their	  INR	  values	  had	  been	  in	  the	  therapeutic	  INR	  range	  at	  the	  last	  two	  consecutive	  laboratory	  controls.	  Exclusion	  criteria	  were	  severe	  liver	  disease	  and	  renal	  failure.	  The	  warfarin	  maintenance	  dose	  in	  each	  patient	  had	  been	  identified	  by	  specialized	  medical	  doctors	  with	  the	  help	  of	  a	  computerized	  algorithm	  (Parma	  4.1,	  Instrumentation	  Laboratory	  Company,	  MA,	  USA)	  	  (Manotti	  C,	  2001),	  which	  is	  based	  on	  a	  regression	  model	  that	  considers	  the	  weekly	  variations	  of	  INR.	  Several	  studies	  showed	  that	  Parma	  4.1	  	  significantly	  improves	  the	  quality	  of	  treatment,	  compared	  to	  the	  doctor-­‐prescribed	  method	  (Ageno	  W,	  1998;	  Manotti	  C,	  2001;	  Poller	  L,	  2004).	  	  Data	  collection	  Demographic	  data	  (age,	  gender,	  height,	  weight,	  body	  mass	  index),	  indication	  for	  anticoagulant	  therapy,	  concomitant	  diseases,	  co-­‐medications,	  INR	  target	  range,	  warfarin	  maintenance	  dose	  were	  collected.	  Concomitant	  medications	  were:	  antihypertensives	  (ACE-­‐inhibitors,	  Angiotensin	  II	  receptor	  antagonists,	  alpha-­‐blockers,	  vasodilators	  and	  dihydropyridines	  calcium	  channel	  blockers),	  diuretics	  (loop,	  thiazide	  and	  potassium-­‐sparing	  diuretics:	  diuretics),	  antithrombotic	  drugs	  (P2Y12	  antagonists	  and	  aspirin),	  proton	  pump	  inhibitors,	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statins,	  oral	  glucose	  lowering	  agents,	  allopurinol,	  antibiotics,	  carbamazepine,	  tapazole,	  antiarrhythmic	  drugs	  (Class	  I,	  II,	  III	  except	  amiodarone,	  IV	  and	  V),	  amiodarone	  and	  other	  drugs	  (i.e.	  antidepressant,	  antipsychotic,	  anticonvulsant	  except	  carbamazepine,	  L-­‐thyroxin	  and	  analgesic).	  	  	  Laboratory	  methods	  Venous	  blood	  was	  collected	  in	  0.109	  M	  sodium	  citrate	  (9:1	  vol:vol)	  and	  in	  K3-­‐EDTA	  tubes.	  Plasma	  and	  cells	  were	  separated	  after	  centrifugation	  at	  4000	  g	  for	  30	  min.	  DNA	  was	  isolated	  from	  leukocytes	  	  using	  an	  automated	  extraction	  system	  (Abbott	  m2000sp,	  Abbott	  Molecular	  Inc.,	  IL,	  USA)	  following	  the	  manufacturer’s	  recommendations.	  The	  DNA	  samples	  were	  eluted	  in	  100	  μl	  	  water	  and	  stored	  at	  –20°C	  until	  processed.	  The	  DNA	  concentration	  in	  the	  samples	  ranged	  	  between	  25	  and	  40	  ng/μl,	  with	  a	  purity	  (measured	  by	  the	  269/280	  ratio)	  ranging	  	  between	  1.4	  and	  1.7,	  which	  was	  considered	  adequate	  for	  	  further	  analysis.	  PT	  was	  measured	  using	  the	  human	  recombinant	  thromboplastin	  RecombiPlasTin	  (HemosILTM,	  Instrumentation	  Laboratory,	  USA),	  and	  an	  Electra	  1600	  coagulometer	  (MA,	  USA).	  The	  laboratory	  performed	  regular	  external	  quality	  control	  exercises.	  Five	  common	  CYP2C9	  (*2,	  *3,	  *5,	  *6,	  *11)	  and	  3	  common	  VKORC1	  (3673G→A,	  6484C→T,	  6853G→C)	  single	  nucleotide	  polymorphisms	  (SNPs)	  were	  assessed	  through	  allele	  specific	  primer	  extension	  PCR.	  CYP2C9	  allele	  designations	  refer	  to	  those	  defined	  by	  the	  Cyto-­‐chrome	  P450	  Allele	  Nomenclature	  Committee	  (http://www.cypalleles.ki.se).	  Genotype	  analysis	  was	  performed	  using	  INFINITI™	  Analyzer,	  which	  	  is	  an	  automated,	  multiplexing,	  continuous	  flow,	  random	  access	  microarray	  platform	  (Autogenomics,	  CA,	  USA).	  	  	  Input	  variables	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A	  total	  of	  48	  clinical	  and	  genetic	  variables,	  known	  to	  influence	  the	  pharmacological	  response	  to	  warfarin,	  were	  available	  for	  mathematical	  modelling	  (Table	  1).	  	  Statistical	  analysis	  Data	  are	  shown	  as	  means	  and	  standard	  deviations	  (SD)	  or	  medians	  and	  interquartile	  ranges	  (IQR),	  according	  to	  their	  distribution,	  which	  was	  evaluated	  using	  the	  Kolmogorov-­‐Smirnov	  test.	  The	  Spearman's	  correlation	  test	  was	  used	  to	  analyse	  the	  data.	  P	  values	  <0.05	  were	  considered	  statistically	  significant.	  The	  sample	  selected	  for	  the	  analysis	  (n	  =	  377)	  is	  relatively	  large,	  as	  it	  is	  required	  by	  the	  nature	  of	  the	  research	  question,	  to	  allow	  enough	  variability	  to	  make	  meaningful	  inferences	  as	  to	  the	  predictive	  capacity	  of	  the	  single	  variables.	  Multivariate	  analysis	  was	  carried	  out	  with	  supervised	  ANN,	  according	  to	  the	  method	  already	  adopted	  (Penco	  S,	  2008).	  The	  choice	  of	  a	  relatively	  unusual	  and	  sophisticated	  inferential	  technique	  such	  as	  ANN	  is	  motivated	  by	  the	  fact	  that	  the	  underlying	  relation	  to	  be	  estimated	  among	  our	  independent	  sample	  variables	  and	  the	  dependent	  variable	  (the	  optimal	  dose	  of	  warfarin)	  is	  extremely	  complex	  and	  there	  is	  no	  reliable	  a-­‐priori	  statistical	  model	  to	  refer	  to.	  ANNs	  self-­‐adjust	  their	  structure	  as	  they	  learn	  from	  their	  own	  errors,	  are	  able	  to	  handle	  a	  very	  high	  number	  of	  variables	  simultaneously,	  irrespective	  of	  their	  underlying	  degree	  of	  non-­‐linearity,	  and	  lead	  to	  structurally	  robust	  results	  even	  when	  the	  underlying	  statistical	  process	  is	  not	  well	  understood,	  thereby	  allowing	  to	  deal	  with	  many	  sources	  of	  inferential	  trouble	  such	  as	  outliers,	  collinear	  interactions	  among	  variables	  and	  hidden	  variables	  (Buscema	  M,	  1998).	  In	  particular,	  we	  work	  with	  the	  family	  of	  Supervised	  ANNs,	  that	  is	  to	  say,	  with	  ANN	  that	  tackle	  problems	   where	   an	   external,	   objective	   target	   output	   can	   be	   fixed,	   so	   that	   they	   learn	   by	  examples	  (the	  training	  set,	  that	  is,	  a	  suitable	  sub-­‐sample	  of	  the	  whole	  database),	  calculating	  an	  error	   function	  during	  the	  training	  phase,	  and	  adjusting	  the	  connection	  strengths	   in	  order	   to	  minimize	   the	   error	   function	   until	   a	   satisfactory	   and	   stable	   level	   of	   accuracy	   in	   the	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prediction/classification	   task	   is	   reached.	  This	   type	  of	  ANNs	   thus	  computes	  a	   function	  of	   the	  form:	  y	  =	  f(x,w*),	  where	  x	  is	  the	  input,	  y	  is	  the	  output	  and	  	  w*	  is	  the	  set	  of	  ANN	  weights	  (the	  function	  parameters)	   that	  encode	   the	  ANN's	  approximate	   reconstruction	  of	   the	   structure	  of	  the	  function.	  	  In	  order	  to	  cut	  down	  of	  the	  number	  of	  irrelevant	  variables	  in	  the	  database	  (i.e.,	  the	  variables	  that	  do	  not	  carry	  any	  meaningful	   information	  for	  the	  prediction	  task),	  which	  cause	  a	   loss	   in	  the	  power	   of	   our	   inferences,	  we	  have	   employed	   a	   special	   ‘artificial	   organism’	   called	  TWIST	  (Buscema	  M,	  2005),	  suitably	  designed	  for	  sorting	  out	  the	  most	  relevant	  variables	  for	  the	  sake	  of	  prediction/classification.	  It	  consists	  of	  a	  combination	  of	  two	  already	  known	  systems:	  T&T	  and	   IS.	   The	   T&T	   system	   is	   a	   robust	   data	   re-­‐sampling	   technique	   that	   is	   able	   to	   arrange	   the	  source	  sample	  into	  sub-­‐samples,	  all	  of	  which	  possessing	  a	  similar	  probability	  density	  function.	  In	   this	  way,	   the	   database	   is	   split	   into	   two	   or	  more	   sub-­‐samples	   in	   order	   to	   train,	   test	   and	  validate	   the	  ANN	  models	  as	  effectively	  as	  possible	  on	   the	  basis	  of	   the	  available	  data.	  The	   IS	  system	  is	  an	  evolutionary	   'wrapper'	  system	  that	  selects	  variables	   in	  order	  to	  minimize	  their	  number	   while	   preserving	   the	   actual	   amount	   of	   task-­‐relevant	   information	   contained	   in	   the	  data-­‐set.	   The	   combined	   action	   of	   these	   two	   systems	   allows	   us	   to	   increase	   substantially	   the	  inferential	   power	   of	   our	   ANN	   system,	   while	   circumventing	   at	   the	   same	   time	   a	   few	   major	  technical	   issues.	   Both	   systems	   are	   based	   on	   a	   Genetic	   Algorithm,	   the	   Genetic	   Doping	  Algorithm	  (GenD)	  developed	  at	  Semeion	  Research	  Centre	   (Rome,	   Italy)	   (Buscema	  M,	  2004).	  The	  TWIST	  system	  is	  described	  in	  detail	  in	  the	  appendix,	  and	  Figure	  1	  below	  is	  a	  snapshot	  of	  TWIST	  at	  work	  during	  the	  variables	  selection	  task.	  The	  TWIST	  pre-­‐processing	  singles	  out	  the	  variables	  that	  prove	  to	  be	  most	  significant	  for	  the	  prediction/classification	   task,	   while	   producing	   at	   the	   same	   time	   the	   training	   set	   and	   the	  testing	   set,	   which	   are	   extracted	   from	   a	   probability	   distribution	   very	   close	   to	   the	   one	   that	  provided	  the	  best	  performance	  in	  the	  task.	  As	  to	  the	  prediction/classification	  task,	  it	  is	  carried	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  Patients’	  characteristics	  A	  total	  of	  377	  patients	  met	  the	  inclusion	  criteria	  and	  were	  included	  in	  the	  analysis.	  The	  most	  relevant	   clinical	   characteristics	   of	   the	   enrolled	   patients	   are	   described	   in	   table	   2.	   The	  most	  frequent	  clinical	  indication	  for	  anticoagulation	  was	  atrial	  fibrillation	  (69%);	  other	  indications	  included	  heart	  valve	  prosthesis	  (10%)	  and	  pulmonary	  embolism	  (8%).	  The	  large	  majority	  of	  patients,	  325,	  86%)	  were	  on	  concurrent	  drug	  treatment:	  on	  average,	  they	  were	  taking	  3	  (IQR	  1-­‐4)	  medications	  potentially	  interacting	  with	  warfarin.	  The	  median	  weekly	  maintenance	  dose	  (WMD)	  of	  warfarin	  was	  22.5	  mg	  (IQR	  16.3-­‐28.8mg).	  Thirteen	  patients	  whose	  INR	  values	  were	  not	   within	   the	   therapeutic	   range	   were	   erroneously	   included	   in	   the	   analysis:	   their	   median	  weekly	  maintenance	  dose	  was	  21.4	  mg	  (IQR	  12.2-­‐30.0	  mg),	  the	  INR	  was	  higher	  than	  3.0	  (INR	  3.7	  and	  4.3)	  in	  2,	  and	  lower	  than	  2.0	  in	  11	  (median	  INR	  1.5,	  IQR	  1.5-­‐1.7).	  We	  believe	  that	  this	  mistake	  cannot	  modify	   the	  results	  of	   the	  study:	   the	  difference	  between	  the	  warfarin	  weekly	  dose	  determining	  the	  target	  INR	  and	  the	  wrong	  one	  was	  low:	  1.7	  mg	  (21.4	  mg	  vs	  19.7	  mg).	  The	  frequencies	  of	  CYP2C9	  and	  VKORC1	  genotypes	  	  are	  reported	  in	  table	  3.	  Variant	  VKORC1	  genotypes	  	  were	  present	  in	  about	  70%	  of	  patients,	  while	  variant	  CYP2C9	  genotypes	  were	  present	  in	  38%.	  Effect	  of	  variables	  on	  warfarin	  maintenance	  dose	  Age	  and	  atrial	  fibrillation	  were	  inversely	  associated	  with	  the	  average	  therapeutic	  dose	  of	  warfarin,	  while	  weight,	  height,	  	  BMI,	  deep	  vein	  thrombosis	  and	  other	  clinical	  indications	  for	  treatment	  were	  directly	  associated	  with	  it	  (Table	  4)	  The	  average	  WMD	  of	  warfarin	  was	  positively	  associated	  with	  the	  wilde	  type	  genotype	  of	  CYP2C9	  (*1/*1)	  and	  negatively	  associated	  with	  genotypes	  *1/*3	  and	  *2/*3.	  Our	  results	  are	  in	  line	  with	  a	  recent	  meta-­‐analysis	  that	  showed	  that,	  compared	  with	  subjects	  with	  	  wild	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genotype	  (*1/*1),	  WMD	  of	  warfarin	  is	  22%,	  36%,	  43%,	  53%,	  and	  76%	  lower	  among	  individuals	  with	  *1/*2,	  *1/*3,	  *2/*2,	  *2/*3,	  and	  *3/*3	  genotypes	  (McClain	  MR,	  2008).	  Wilde-­‐type	  VKORC1	  genotypes	  (3673GG,	  6484CC,	  6853GG)	  were	  posively	  associated	  with	  the	  maintenance	  dose	  of	  warfarin,	  while	  genotype	  variants	  3673AA,	  6484TT	  and	  6853CC	  were	  inversely	  associated	  with	  it.	  Our	  results	  are	  consistent	  with	  previous	  reports	  (Geisen	  C,	  2005;	  McClain	  AR,	  2008;	  Spreafico	  M,	  2008;	  Wadelius	  M,	  2009;	  Jorgensen	  AL,	  2012).	  No	  statistically	  significant	  associations	  with	  warfarin	  dose	  and	  concomitant	  medications	  were	  found.	  	  Artificial	  neural	  network	  analysis	  Forty-­‐eight	  variables,	  including	  demographic,	  clinical	  and	  genetic	  data	  (5	  CYP2C9	  and	  3	  VKORC1	  genetic	  variants)	  were	  entered	  into	  the	  Twist®	  system,	  which	  can	  select	  fundamental	  variables	  during	  their	  evolution	  in	  search	  for	  the	  best	  predictive	  model.	  The	  twist	  system	  selected	  23	  variables	  (table	  5)	  carrying	  the	  maximal	  amount	  of	  information	  to	  build	  up	  a	  predictive	  model.	  The	  final	  model,	  based	  on	  these	  23	  variables,	  expressed	  a	  functional	  approximation	  of	  the	  actual	  dose	  of	  warfarin	  within	  a	  validation	  protocol	  based	  on	  a	  tripartite	  division	  of	  the	  data	  set	  (training,	  testing,	  validation).	  In	  this	  procedure	  the	  study	  sample	  was	  randomly	  divided	  into	  two	  main	  sub-­‐samples:	  the	  tuning	  set	  sub-­‐sample	  	  and	  the	  prediction	  sub-­‐sample,	  	  which	  accounted	  for	  about	  50%	  of	  the	  tuning	  sample.	  The	  tuning	  data	  set	  was	  in	  turn	  subdivided	  in	  two	  halves,	  	  the	  training	  sample	  and	  the	  testing	  sample.	  This	  was	  done	  five	  times.	  During	  the	  training	  phase,	  the	  ANN	  learned	  a	  model	  of	  data	  distribution	  and	  then,	  on	  the	  basis	  of	  such	  a	  model,	  blindly	  made	  a	  functional	  approximation	  of	  dependent	  variable	  in	  the	  testing	  set.	  Training	  and	  testing	  sets	  were	  then	  reversed	  and	  consequently	  10	  analyses	  for	  every	  model	  employed	  were	  conducted.	  The	  best	  performing	  model	  was	  then	  selected	  and	  used	  to	  predict	  the	  warfarin	  dose	  in	  the	  prediction	  set,	  which	  had	  been	  taken	  apart	  during	  all	  the	  procedure.	  Also	  in	  this	  case	  the	  prediction	  was	  done	  blindly.	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  The	  number	  of	  patients	  on	  oral	  anticoagulant	  therapy	  continues	  to	  increase	  worldwide.	  Warfarin	  remains	  the	  most	  frequently	  prescribed	  oral	  anticoagulant	  drug	  because	  of	  its	  low	  cost,	  proven	  efficacy	  and	  the	  availability	  of	  antidotes	  to	  treat	  patients	  with	  bleeding	  complications.	  	  Because	  genetic	  variation	  contributes	  to	  the	  observed	  high	  inter-­‐individual	  variability	  in	  dose-­‐requirements,	  which	  can	  potentially	  increase	  the	  risk	  of	  thrombosis	  or	  bleeding,	  the	  US	  Food	  and	  Drug	  Administration	  (FDA)	  supported	  the	  use	  of	  genotyping	  to	  guide	  warfarin	  dosing	  (http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm).	  In	  the	  present	  study,	  	  we	  tested	  the	  efficacy	  of	  warfarin	  dosing	  during	  maintenance	  treatment,	  based	  on	  a	  large	  number	  of	  genetic	  and	  clinical	  factors	  that	  were	  analyzed	  by	  artificial	  neural	  networks	  (ANN),	  which	  are	  effective	  tools	  for	  clinical	  decision-­‐making.	  	  	  In	  the	  validation	  cohort,	  our	  model	  displayed	  high	  accuracy	  and	  explained	  an	  average	  absolute	  error	  of	  5.7	  mg/week	  and	  from	  50%	  to	  71%	  of	  weekly	  warfarin	  dose	  variability.	  The	  dose	  prediction	  was	  particularly	  accurate	  for	  the	  subset	  of	  patients	  requiring	  weekly	  doses	  of	  warfarin	  ≤21	  mg	  (correct	  dose	  identification	  in	  72%	  of	  patients)	  or	  22-­‐48	  mg	  (74%).	  In	  the	  subset	  of	  patients	  requiring	  higher	  weekly	  warfarin	  doses	  (≥49	  mg),	  the	  algorithm	  did	  not	  perform	  successfully,	  most	  likely	  because	  only	  15	  patients	  belonged	  to	  this	  subgroup.	  Previous	  studies	  reported	  on	  the	  peformance	  of	  pharmacogenetic	  algorithms	  in	  warfarin	  dosing	  (Lenzini	  P,	  2010;	  IVPC	  2009,	  Gong	  IY,	  2011;	  Zambon	  CF,	  2011).	  Table	  7	  shows	  that	  the	  performance	  of	  our	  algorithm	  appears	  to	  be	  superior	  to	  those	  of	  the	  2	  published	  studies	  that	  mostly	  enrolled	  Caucasian	  patients	  (Table	  7)	  (IVPC	  2009,	  Zambon	  CF,	  2011).	  The	  results	  of	  the	  other	  published	  studies	  can	  be	  hardly	  compared	  to	  ours,	  because	  they	  mostly	  enrolled	  non-­‐Caucasian	  patients,	  who	  have	  different	  	  prevalences	  of	  CYP2C9	  and	  VKORC1	  polymorphisms	  (Jorgensen	  AL,	  2012).	  The	  higher	  performance	  of	  our	  model	  may	  be	  explained	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by	  the	  high	  accuracy	  of	  ANN	  to	  identify	  complex,	  non-­‐linear	  relationships	  among	  genetic	  and	  clinical	  variables	  in	  a	  global	  analysis	  and	  by	  the	  much	  higher	  number	  of	  variables	  (23)	  that	  were	  retained	  in	  our	  final	  model,	  compared	  to	  other	  models	  (Moreno	  L,	  1995).	  	  Considering	  the	  promising	  results	  of	  our	  study,	  we	  believe	  that	  the	  performance	  of	  the	  ANN	  model	  should	  be	  tested	  a	  prospective	  study	  assessing:	  i)	  the	  time	  within	  therapeutic	  INR	  range	  during	  VKA	  therapy,	  	  ii)	  the	  number	  of	  thromboembolic	  and	  bleeding	  events	  and,	  iii)	  cost	  effectiveness,	  compared	  to	  the	  best	  care.	  	  A	  randomized	  trial	  compared	  standard	  dosing	  regimen	  with	  two	  genotype-­‐guided	  algorithms,	  based	  on	  the	  IWPC	  (IWPC	  2009)	  and	  Gage	  algorithms	  (Gage	  BF,	  2008)	  that	  incorporate	  both	  clinical	  and	  genetic	  factors.	  Primary	  outcomes	  were	  percentage	  of	  out-­‐of-­‐range	  INR	  at	  1	  and	  3	  months	  and	  percentage	  of	  time	  in	  therapeutic	  range.	  The	  combined	  genotype-­‐guided	  prescription	  cohort	  demonstrated	  superior	  outcomes	  with	  respect	  to	  both	  primary	  end	  points	  at	  3	  months	  (30%	  vs	  42%	  for	  out-­‐of-­‐range	  and	  71%	  vs	  59%	  for	  therapeutic	  range).	  Moreover,	  serious	  events	  were	  significantly	  less	  frequent	  in	  the	  genotype-­‐guided	  cohort	  (4.5%	  vs	  9.4%	  of	  patients;	  p	  <	  0.001).	  It	  should	  be	  noted	  that	  there	  was	  no	  difference	  in	  the	  primary	  outcome	  between	  the	  two	  genotype-­‐based	  algorithms.	  	  In	  the	  last	  years,	  new	  oral	  direct	  anticoagulants	  (NOA)	  have	  been	  developed	  as	  alternatives	  to	  warfarin,	  with	  at	  least	  equal	  efficacy	  and	  safety,	  wider	  therapeutic	  range,	  less	  complex	  pharmacodynamics,	  and	  no	  need	  for	  laboratory	  monitoring.	  However,	  there	  are	  patients,	  like	  those	  with	  severe	  renal	  function	  impairment,	  who	  cannot	  be	  treated	  with	  NOA.	  Moreover,	  NOA	  are	  very	  expensive	  and	  no	  specific	  antidotes	  to	  treat	  patients	  with	  bleeding	  complications	  have	  been	  developed	  yet.	  	  Therefore,	  	  it	  can	  be	  easily	  predicted	  that	  replacement	  of	  warfarin	  by	  NOA	  will	  be	  a	  slow	  and	  partial	  process.	  As	  a	  consequence,	  efforts	  are	  still	  needed	  to	  improve	  our	  ability	  to	  predict	  the	  correct	  dose	  of	  warfarin.	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TABLES	  
 Table	  1:	  Variables	  that	  have	  been	  considered	  in	  our	  analysis	  
 
1	   	  Male	  gender	   18	   CYP2C9*2*3	   35	   Antihypertensive	  drugs	  2	   Female	  gender	   19	   CYP2C9*3*3	   36	   Antiarrhythmic	  drugs	  3	   Age	   20	   CYP2C9*1*5	   37	   Diuretics	  4	   Weight	   21	   CYP2C9*5*5	   38	   Amiodarone	  5	   Height	   22	   CYP2C9*1*6	   39	   Antithrombotic	  drugs	  6	   Body	  Mass	  Index	   23	   CYP2C9*6*6	   40	   Proton	  pump	  inhibitors	  7	   Deep	  vein	  thrombosis	   24	   CYP2C9*1*11	   41	   Statins	  8	   Pulmunary	  embolism	   25	   CYP2C9*11*11	   42	   Oral	  glucose	  lowering	  agents	  	  9	   Atrial	  fibrillation	   26	   VKORC1	  3673	  GG	  	   43	   Allopurinol	  10	   Heart	  Valve	   27	   VKORC1	  3673	  GA	  	   44	   Antibiotics	  	  11	   Cardiomyopathy	   28	   VKORC1	  3673	  AA	   45	   Carbamazepine	  12	   Stroke	   29	   VKORC1	  6484	  CC	   46	   Tapazole	  13	   Other	  indications	   30	   VKORC1	  6484	  CT	   47	   Other	  drugs	  14	   CYP2C9*1*1	   31	   VKORC1	  6484	  TT	   48	   Warfarin	  weekly	  maintenance	  dose	  15	   CYP2C9*1*2	   32	   VKORC1	  6853	  GG	   	   	  16	   CYP2C9*2*2	   33	   VKORC1	  6853	  GC	  	   	   	  17	   CYP2C9*1*3	   34	   VKORC1	  6853	  CC	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  Table	  2:	  Patients’	  characteristics	  
 
Variables	   	  Age(years),	  median	  (IQR)	   76	  (70-­‐80)	  	  Men,	  n	  (%)	   186	  (49%)	  Body	  mass	  index,	  median	  (IQR)	   18.0	  (16-­‐20)	  Indication	  for	  anticoagulation,	  n	  (%)	   	  	  	  -­‐	  Atrial	  fibrillation	   261	  (69%)	  	  	  -­‐	  Artificial	  heart	  valves	   39	  (10%)	  	  	  -­‐	  Pulmonary	  embolism	   30	  (8%)	  	  	  -­‐	  Deep	  vein	  thrombosis	   21	  (6%)	  	  	  -­‐	  Cardiomyopathy	   15	  (4%)	  	  	  -­‐	  Stroke	   13	  (3%)	  	  	  -­‐	  Other	  indications	   14	  (4%)	  Number	  of	  concomitant	  medications	  per	  patient,	  median	  (IQR)	   3	  (1-­‐4)	  Patients	  with	  no	  concomitant	  medications,	  n	  (%)	   53	  (14%)	  Numebr	  (%)	  of	  patients	  on	  concomitant	  medication	  with,	  :	   	  	  	  -­‐	  Antihypertensive	  drugs	   209	  (55%)	  	  	  -­‐	  Antiarrhythmic	  drugs	   192	  (51%)	  	  	  -­‐	  Diuretics	   133	  (35%)	  	  	  -­‐	  Amiodarone	   69	  (18%)	  	  	  -­‐	  Antithrombotic	  drugs	   68	  (18%)	  	  	  -­‐	  Proton	  pump	  inhibitors	   58	  (15%)	  	  	  -­‐	  Statins	   50	  (13%)	  	  	  -­‐	  Oral	  glucose	  lowering	  agents	   32	  (9%)	  	  	  -­‐	  Allopurinol	   18	  (5%)	  	  	  -­‐	  Antibiotics	  	   13	  (3%)	  	  	  -­‐	  Carbamazepine	   1	  (0.3%)	  	  	  -­‐	  Tapazole	   1	  (0.3%)	  	  	  -­‐	  Other	  drugs	   123	  (32%)	  Weekly	  mean	  therapeutic	  warfarin	  dose,	  mg	  per	  week	  (±SD)	   23.7	  mg	  (±11.5)	  Weekly	  median	  therapeutic	  warfarin	  dose,	  mg	  per	  week	  (IQR)	   22.5	  mg	  (15.6-­‐29.4)	  	  
 SD=	  standard	  deviation;	  IQR=	  interquartile	  range.	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 Table	  3	  	  Prevalences	  of	  genetic	  CYP2C9	  and	  VKORC1	  genotypes,	  and	  allele	  frequency	  of	  CYP2C9	  	  Gene	   Genotype	   	   n	  (%)	   Gene	   Genotype	   n	  (%)	  CYP2C9	   *1/*1	   235	  (62.3%)	   VKORC1	   3673GG	  	   111	  (29%)	  	   *1/*2	   85	  (22.5%)	   	   3673GA	  	   189	  (50%)	  	   *1/*3	   44	  (11.7%)	   	   3673AA	   77	  (20%)	  	   *2/*2	   4	  (1.1%)	   	   6484CC	   107	  (28%)	  	   *2/*3	   7	  (1.8%)	   	   6484CT	   195	  (52%)	  	   *3/*3	   1	  (0.3%)	   	   6484TT	   75	  (20%)	  	   *11/*11	   1	  (0.3%)	   	   6853GG	   101	  (27%)	  	   	   	   	   6853GC	  	   195	  (51%)	  	   	   	   	   6853CC	   81	  (22%)	  	   	   	   	   	   	  CYP2C9	   Allele	   	   n	  (%)	   	   	   	  	   *1	   599	  (79.4%)	   	   	   	  	   *2	   100	  (13.3%)	   	   	   	  	   *3	   53	  (7%)	   	   	   	  	   *11	   2	  (0.3%)	   	   	   	  	  
 26 
 
 Table	  4	  Correlation	  between	  the	  weekly	  therapeutic	  warfarin	  dose	  with	  clinical	  and	  genetic	  variables.	  
 Variables	   r	   p	  VKORC1	  6484TT	   -­‐0.31	   <0.01	  VKORC1	  6853	  CC	  	   -­‐0.31	   <0.01	  VKORC1	  3673	  AA	  	   -­‐029	   <0.01	  Age	   -­‐0.21	   <0.01	  CYP2C9*1/*3	   -­‐0.14	   <0.01	  CYP2C9*2/*3	   -­‐0.14	   <0.01	  Atrial	  fibrillation	   -­‐0.14	   0.006	  VKORC1	  6484	  CC	  	   0.33	   <0.01	  VKORC1	  3673	  GG	   0.33	   <0.01	  VKORC1	  6853	  GG	   0.30	   <0.01	  Body	  Mass	  Index	   0.21	   <0.01	  Weight	   0.21	   <0.01	  Height	   0.15	   <0.05	  Deep	  vein	  thrombosis	   0.15	   <0.05	  CYP2C9*1/1	   0.13	   <0.05	  Other	  indications	  for	  Warfarin	   0.12	   <0.05	  	  Spearman	  test	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 Table	  5.	  Variables	  that	  were	  selected	  by	  the	  TWIST	  system	  




 Table	  6	  Results	  obtained	  by	  ANN	  on	  the	  validation	  cohort	  	   	  	  	  	  	  	  	  	  	  MAE:	  mean	  absolute	  error;	  R2	  is	  the	  coefficient	  of	  determination;	  %=	  percentage	  of	  patients	  predicted	  dose	  within	  20%	  of	  the	  actual	  dose;	  ANN:	  artificial	  network	  analysis;	  *mean	  (SD)	  	  
ANN	   n	  (%)	   MAE	  (mg)*	  	   R2	   %	  correctly	  classified	  
≤	  21	  mg/week	   170	  (45)	   3.86	  (0.92)	   0.67	   72	  
22-­‐48	  mg/week	   193	  (51)	   5.45	  (1.02)	   0.51	   74	  
≥49	  mg/week	   14	  (4)	   24.2	  (6.3)	   0.15	   0	  
Total	   377	  (100)	   5.72	  (0.94)	   0.48	   70	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 Table	  7.	  Comparison	  of	  the	  performances	  	  of	  different	  pharmacogenetic	  algorithms	  	   	  	  Study	   	  	  n	   	  Caucasians	  (%)	   	  	  R2	   	  MAE	  (mg)	   %	  of	  patients	  who	  were	  correctly	  classified	  	  This	  study	  	   377	   100	   0.48	   5.72	   70	  IWPC	  (IWPC,	  2009)	   1009	   56	   0.43	   8.5	   ≈45	  Zambon	  (Zambon,	  2011)	  	   97	   100	   0.56	   7.0	   52	  	  n:	  number	  of	  subjects	  included;	  MAE:	  mean	  absolute	  error;	  R2	  is	  the	  coefficient	  of	  determination;	  %=	  percentage	  of	  patients	  for	  whom	  the	  predicted	  dose	  within	  20%	  of	  the	  actual	  dose	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APPENDIX	  The	  TWIST	  methodology	  	  	  TWIST	  (Buscema	  M,	  2005)	  is	  an	  ensemble	  of	  two	  distinct	  algorithms:	  T&T	  and	  I.S.	  	  	  
A.1	  T&T	  	  The	   “Training	   and	   Testing”	   algorithm	   (T&T)	   is	   based	   on	   a	   population	   of	   n	   ANNs,	  managed	  by	  an	  evolutionary	  system.	   In	   its	  simplest	   form,	   this	  algorithm	  reproduces	  several	  distribution	  models	  of	  the	  complete	  dataset	  DΓ	  (one	  for	  every	  ANN	  of	  the	  population)	  in	  two	  subsets	   ( ,	   the	  Training	   Set	   and	   ,	   the	  Testing	   Set).	  During	   the	   learning	  process	   each	  ANN,	   according	   to	   its	   own	   data	   distribution	   model,	   is	   trained	   on	   the	   subsample	   	   and	  
blind-­‐validated	  on	  the	  subsample	   .	  The	  performance	  score	  reached	  by	  each	  ANN	  in	  the	  testing	  phase	  represents	  its	  “fitness”	  value	  (i.e.,	  the	  individual	  probability	  of	  evolution).	  The	  genome	  of	  each	  “ANN-­‐individual”	  thus	  codifies	   a	   data	   distribution	   model	   with	   an	   associated	   validation	   strategy.	   The	   n	   data	  distribution	   models	   are	   combined	   according	   to	   their	   fitness	   criteria	   using	   an	   evolutionary	  algorithm.	  The	   fitness-­‐based	   selection	  of	   “ANN-­‐individuals”	  determines	   the	   evolution	  of	   the	  population;	   that	   is,	   the	  progressive	   improvement	   of	   performance	  of	   each	  network	  until	   the	  optimal	   performance	   is	   reached,	   which	   is	   equivalent	   to	   the	   optimal	   splitting	   of	   the	   global	  dataset	  into	  subsets.	  The	  evolutionary	  algorithm	  ruling	  this	  process,	  named	  “Genetic	  Doping	  Algorithm”	   (GenD)	   (Buscema	   M,	   2004),	   is	   similar	   to	   a	   genetic	   algorithm	   (i.e.	   it	   works	   by	  crossover	   and	  mutation	  genetic	  operators),	   but	  maintains	   a	   constitutional	   instability	   across	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the	   evolutionary	   process,	   thereby	   sustaining	   a	   natural	   proliferation	   of	   biodiversity	   and	   a	  continuous	  meta-­‐evolution	  of	  the	  population.	  	  The	  working	  of	  T&T	  is	  organized	  into	  two	  phases:	  	  1)	   Preliminary	   phase:	   in	   this	   phase	   an	   evaluation	   of	   the	   parameters	   of	   the	   fitness	  function	  that	  will	  be	  used	  on	  the	  global	  dataset	  is	  performed.	  During	  this	  phase,	  an	  inductor	  
	  is	  set	  up,	  which	  consists	  of	  an	  Artificial	  Neural	  Network	  equipped	  with	  a	  standard	  Back	  Propagation	  algorithm.	  For	  this	  inductor,	  the	  optimal	  configuration	  is	  determined	  at	  the	  
end	  of	  different	   training	   trials	   on	   the	   global	  dataset	   .	   In	   this	  way,	   the	   configuration	   that	  most	  “suits”	  the	  available	  dataset	  is	  determined:	  The	  number	  of	  layers	  and	  hidden	  units,	  and	  some	  possible	  generalizations	  of	  the	  standard	  learning	  law.	  The	  parameters	  thus	  determined	  define	  the	  configuration	  and	  the	  initialization	  of	  all	  the	  ANN-­‐individuals	  of	  the	  population,	  and	  will	   subsequently	   stay	   fixed	   in	   the	   following	   computational	   phase.	   Basically,	   during	   this	  preliminary	  phase	  there	  is	  a	  fine-­‐tuning	  of	  the	  inductor	  that	  defines	  the	  fitness	  values	  of	  the	  population’s	  individuals	  during	  evolution.	  The	   accuracy	   of	   the	   ANN	   performance	   upon	   the	   testing	   set	  will	   be	   the	   fitness	   of	   that	  individual	   (that	   is,	   of	   the	   trial-­‐specific	   tentative	   distribution	   into	   two	   halves	   of	   the	   whole	  dataset).	  	  2)	  Computational	  phase:	  The	  system	  extracts	   from	  the	  global	  dataset	   the	  best	   training	  and	   testing	   sets.	  During	   this	  phase,	   the	  ANN-­‐individuals	   carry	  out	   their	   computational	   task,	  based	   upon	   the	   established	   configuration	   and	   the	   initialization	   parameters.	   From	   the	  evolution	   of	   the	   population,	   managed	   by	   the	   GenD	   algorithm,	   the	   best	   distribution	   of	   the	  global	  dataset	  DΓ	  into	  two	  subsets	  is	  generated,	  starting	  from	  the	  initial	  population	  of	  possible	  
solutions	   .	   Preliminary	   experimental	   sessions	   are	   performed	   using	   several	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different	  ANN	  initializations	  and	  configurations,	   in	  order	  to	  achieve	  the	  best	  partition	  of	  the	  global	  dataset.	  	  	  	  	  A2.	  I.S.	  	  Parallel	   to	   T&T,	   TWIST	   runs	   I.S.	   (Input	   Selection),	   an	   adaptive	   system	   which	   is	   also	  based	  on	   the	  evolutionary	  algorithm	  GenD,	  and	   that	   is	  able	   to	  evaluate	   the	  relevance	  of	   the	  different	  variables	  of	  the	  dataset	  in	  a	  sophisticated	  way.	  Therefore,	  it	  can	  be	  considered	  on	  the	  same	  level	  as	  a	  feature	  selection	  technique.	  From	  a	  formal	  point	  of	  view,	   I.S.	   is	  an	  artificial	  organism	  based	  on	  the	  GenD	  algorithm	  and	   consists	   of	   a	   population	   of	   ANNs,	   in	   which	   each	   one	   carries	   out	   a	   selection	   of	   the	  independent	   variables	   on	   the	   available	   database.	   The	   elaboration	   of	   I.S.,	   as	   for	   T&T,	   is	  developed	  in	  two	  phases:	  	  
1)	  Preliminary	  phase:	  An	  inductor 	  is	  configured	  to	  evaluate	  the	  parameters	  of	   the	   fitness	   function.	   This	   inductor	   is	   a	   standard	   Back-­‐Propagation	   ANN.	   The	   parameters	  configuration	  and	  the	  initialization	  of	  the	  ANNs	  are	  carried	  out	  with	  particular	  care	  to	  avoid	  possible	   over-­‐fitting	  problems	   that	   can	  be	  present	  when	   the	  database	   is	   characterized	  by	   a	  large	   number	   of	   variables	   that	   describe	   a	   small	   quantity	   of	   data.	   The	   number	   of	   epochs	   	  necessary	  to	  train	  the	  inductor	  is	  determined	  through	  preliminary	  experimental	  tests.	  	  2)	   Computational	   phase:	   The	   inductor	   carries	   out	   its	   computational	   task,	   with	   the	  configuration	   determined	   in	   the	   previous	   phase	   and	   the	   fixed	   initialization	   parameters,	   to	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extract	  the	  most	  relevant	  variables	  of	  the	  training	  and	  testing	  subsets.	  Each	  ANN-­‐individual	  of	  
the	  population	  is	  trained	  on	  the	  training	  set	   	  and	  tested	  on	  the	  testing	  set	   .	  	  The	  evolution	  of	  ANN-­‐individuals	   in	   the	  population	   is	  again	  based	  on	  GenD.	   In	   the	   I.S.	  approach,	   the	   GenD	   genome	   consists	   of	   n	   binary	   values,	   where	   n	   is	   the	   cardinality	   of	   the	  original	  input	  space.	  Every	  gene	  indicates	  whether	  the	  corresponding	  input	  variable	  is	  active	  or	  not	  in	  that	  particular	  selection	  of	  variables.	  For	  each	  genome,	  the	  relevant	  fitness	  value	  is	  computed	  as	  usual.	  Through	  the	  evolutionary	  algorithm,	  the	  different	  “hypotheses”	  of	  variable	  selection,	   generated	   by	   each	   ANNs	   within	   the	   population,	   change	   over	   time,	   at	   each	  generation:	  This	  leads	  to	  the	  selection	  of	  the	  best	  combination	  of	  input	  variables.	  As	  in	  T&T,	  the	  crossover	  and	  mutation	  genetic	  operators	  are	  applied	  on	  the	  ANNs	  population;	  the	  rates	  of	   occurrence	   for	   both	   operators	   are	   adaptively	   self-­‐determined	   by	   the	   system	   at	   each	  generation.	  	  When	  the	  evolutionary	  algorithm	  no	  longer	  improves	  its	  performance,	  the	  process	  stops,	  and	   the	   best	   selection	   of	   the	   input	   variables	   is	   employed	  on	   the	   testing	   subset.	   In	   order	   to	  improve	  the	  speed	  and	  the	  quality	  of	  the	  solutions	  that	  have	  to	  be	  optimized	  with	  respect	  to	  standard	  evolutionary	  algorithms,	  GenD	  does	  not	  breed	  best-­‐performing	  ANN-­‐individuals,	  but	  rather	  most	   representative	   ones.	   The	   selection	   criterion	   is	   therefore	   not	   that	   of	   picking	   up	  momentarily	   brilliant	   but	   possibly	   unreliable	   outliers,	   but	   rather	   reinforcing	   those	  characteristics	  that	  are	  stably	  well	  performing.	   	  
